LCRF Awards $1.5M to Team Targeting EGFR-Mutant Lung Cancer Resistance
Event summary
- $1.5M grant awarded to research team targeting EGFR-mutant lung cancer resistance mechanisms.
- Project led by Kwok-Kin Wong (NYU) and Matthew Meyerson (Harvard) to test novel drug combinations.
- Phase II clinical trial planned for high-risk EGFR-mutant NSCLC patients.
- Research focuses on preventing resistance before it develops, aiming for deeper, more durable responses.
The big picture
This $1.5M grant represents a strategic push to overcome one of the most persistent challenges in EGFR-mutant lung cancer treatment: drug resistance. With median survival still limited to around 39 months despite TKI advancements, this research could significantly alter the treatment landscape. The collaboration between NYU and Harvard researchers builds on foundational work that shaped current targeted therapies, highlighting the continued importance of academic partnerships in oncology innovation.
What we're watching
- Clinical Trial Progress
- The pace at which the planned phase II trial enrolls patients and yields preliminary data will indicate the potential of this novel combination strategy.
- Drug Resistance Mechanisms
- Whether the identified gene deactivation approach can effectively prevent resistance in diverse patient populations remains to be seen.
- Combination Therapy Efficacy
- How the novel drug combinations perform in both mouse models and human trials will determine their potential to extend survival beyond current TKI treatments.